Search

Author/Creator Logan, T.F.

1. 23LBA An open-label, randomized, phase 2 study of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064). (September 2015)

Authors:
Hodi, F.S.; Gibney, G.; Sullivan, R.; Sosman, J.A.; Slingluff, C.L.; Lawrence, D.P.; Logan, T.F.; Schuchter, L.M.; Nair, S.; Fecher, L.; Buchbinder, E.; Ruisi, M.; Kong, G.; Horak, C.; Weber, J.S.
Journal:
European journal of cancer
Issue:
Volume 51:(2015)Supplement 3
Page Start:
S721
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 300 Phase I study of two dosing schedules of the investigational oral pan-RAF kinase inhibitor MLN2480 in patients (pts) with advanced solid tumors or melanoma. Issue 3 (September 2015)

Authors:
Rasco, D.W.; Middleton, M.R.; Gonzalez, R.; Corrie, P.; Pavlick, A.; Lorigan, P.; Plummer, R.; Gore, M.; Herbert, C.; Agarwala, S.S.; Logan, T.F.; Khleif, S.N.; Papadopoulos, K.P.; Rangachari, L.; Suri, A.; Xu, Q.; Kneissl, M.; Bozón, V.; Olszanski, A.J.
Journal:
European journal of cancer
Issue:
Volume 51:Issue 3(2015:Feb.)
Page Start:
S53
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search